Background: Evidence for medical interventions sometimes derives from data that are no longer up to date. These data can influence the out
reviewers and clinicians alike often use studies con ducted a long time ago. What constitutes "a long time" varies according to scientific topic, the interven tion under investigation, methodology, and differences in study population. Whereas the findings of some trials remain valid over time, others become less relevant 13 as concomitant therapies and disease management strategies change. 46 To date there has been little discussion of how often older data are used in systematic reviews, or of the reli ability and relevance of these data, particularly in re gard to systematic reviews containing metaanalyses. To our knowledge, no systematic assessment of the impact of older data on the outcomes of metaanalyses within systematic reviews exists.
In this study we sought to measure how recent is the synthesized evidence in a representative random sample of the Cochrane Database of Systematic Reviews (CDSR), the largest and most comprehensive compila tion of systematic reviews on medical interventions. 79 We also evaluated whether authors of these studies dis cussed the age of trials included in their metaanalyses and the implications of their inclusion. Finally, we sought to determine whether metaanalyses published in highprofile journals in 2005 were more likely to use more recent data and if the authors discussed the im pact of using less recent data on their findings.
Methods
Selecting systematic reviews containing meta-analyses from the CDSR. We used Intercooled Stata 8.2 (College Station, Tex.) to randomly select 10% of the sys tematic reviews included in the CDSR, Issue 4 (2005), keeping those that had not been subsequently with drawn and in which at least 1 metaanalysis had been performed. Selecting only 1 metaanalysis per eligible se lected systematic review, we assessed the time since pub lication of the trials included in the metaanalysis and determined whether the review authors discussed the implications of including less recent trial data. When more than 1 eligible metaanalysis was included in the same systematic review, we retained the metaanalysis that described the primary outcome as defined by the re view. If the review included metaanalyses for more than 1 primary outcome and/or more than 1 comparis on of interventions, we retained the metaanalysis that encompassed the greatest number of trials. In the case of a tie, we chose the metaanalysis with the greatest cu mulative sample size. With further ties for a binary out come we then selected the metaanalysis with more events. Whenever the same trials had been entered as 2 or more comparisons in the same metaanalysis, we counted them as a single trial and calculated its total sample size. Both authors reviewed the random sample and selected relevant metaanalyses. Discrepancies were resolved by consensus.
Data extraction and timing of publication. From each selected metaanalysis, we extracted information on the year of publication of each included trial, the number of participants, and information to calculate the effect size (odds ratio for binary outcomes, standardized or weighted mean difference for continuous outcomes, as specified in each review) and its variance.
Because some authors disseminate their trial results in several articles and meeting abstracts, we consist ently used the publication year for the main article, as selected by the Cochrane reviewers. We validated this process by screening the articles and meeting abstracts from a random sample of 50 trials included in our ana lyses.
For eligible trials in which the Cochrane reviewers had not selected a specific article and year of publica tion or year for data retrieval, we selected the most re cent listed articles or abstracts of the trial; for those studies with entirely unpublished data, we used the year of the last literature search.
We also noted when the last literature search was performed for the systematic review; where this inform ation was unavailable, we recorded the year of last amendment.
Determining the timing of included studies. The definition of an "older" study varies across medical spe cialty and from study to study. For operational pur poses, we used the last 5 years (200105), 10 years (19962005) and 20 years (19862005) from the public ation year of the CDSR database as prespecified cut offs.
Examining implications of including older trials.
We examined whether the authors of each selected system atic review discussed any implications relating to the fact that some or all of the trials included in their meta analyses were older, and whether systematic reviews discussing these implications had included, overall, older trials than those that did not discuss any such is sues.
Sensitivity analyses.
We conducted sensitivity analyses addressing the 5, 10 and 20year estimates using the year of the literature search rather than the CDSR issue date (2005) as a reference year. Using the latter reflects how recent the evidence is for clinical practice at the time of the CDSR issue publication, while using the year of the literature search subtracts the time lag between the literature review and its publication in 2005.
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We also assessed the impact on metaanalyses of in cluding only studies published in the last decade (1996 2005) . Specifically, we recorded how many metaana lyses included such studies, and how many would have reached different inferences for the statistical signific ance of the summary effect (p < 0.05 or p ≥ 0.05) had only these studies been included.
Examining systematic reviews published in major medical journals. We also assessed systematic reviews containing metaanalyses published in 6 major medical journals (New England Journal of Medicine, Journal of the American Medical Association, The Lancet, British Medical Journal, Annals of Internal Medicine and PLoS Medicine) between July and December 2005. The ex amined journals publish systematic reviews of broad medical interest, thus reducing the risk of evaluating topics on few specialties. We followed a protocol similar to that described above for the selection of metaana lyses from systematic reviews in the CDSR.
The year (late 2005) was chosen to be the same as the issue of CDSR that we evaluated. We included only systematic reviews containing at least 1 metaanalysis. When more than 1 metaanalysis of interventions and/or outcomes existed, we followed the same proced ure as for the CDSR systematic reviews to select 1 meta analysis per article. From each eligible metaanalysis we extracted the year of the literature search, the number of synthesized trials, and the number of trials published in the last 5 years (200105), 10 years (19962005) and 20 years (19862005). We did not collect information on sample size per trial and effect size because these were not sufficiently standardized to allow consistent analyses. Otherwise, we evaluated the proportion of re cent data and whether the implications of including older data were discussed by review authors, as de scribed for the analysis of systematic reviews from the CDSR.
Statistical analysis. Summary results were calculated using the DerSimonian and Laird random effects mod el 
Results
Systematic reviews and meta-analyses selected from the CDSR. We randomly sampled 165 of 1651 eligible systematic reviews from the CDSR (Fig. 1) . Of these, 8 were excluded (6 had been withdrawn, and 2 contained no quantitative synthesis). Of the remaining 157 system atic reviews, the selected outcomes were binary in 133 metaanalyses and continuous in 24 metaanalyses. (See Online Appendix 1 for a complete list of the CDSR systematic reviews and metaanalyses included in this study.)
Overall, 1149 trials (1 650 701 participants) were in cluded in the metaanalyses for the primary outcomes for included systematic reviews. There was a median of 5 trials included in each metaanalysis (IQR 37) and of 617 (IQR 2271711) participants.
The median year (IQR) of the last literature search across the 157 systematic reviews was
Of the random sample of 50 trials (of the total 1149 trials encompassed by the 157 metaanalyses included in our review) 44 had the same publication year; for 1 trial, the publication years spanned 2 consecutive years, for another, publication years spanned 3 consecutive years, and in 4 trials publication years spanned a longer period.
Overall, few metaanalyses consisted of data from trials published in the 5 years prior to the publication in the CDSR (2005), and only a quarter of the trials they synthesized had been published within 5 years of the last literature search ( Table 1) . Onethird of metaana lyses included data from trials that had been published in the last 10 years, and twothirds had been published within 10 years of the literature search. A 20year win dow usually captured most or all of the trials that con tributed data to the included metaanalyses.
Almost onethird (30%, 47/157) of metaanalyses in cluded no trials published in the period 19962005, while only 2 metaanalyses (1%, 2/157) consisted en tirely of data from trials published in the same period ( Table 2 ). The respective proportions were 18% (29/157) and 55% (87/157) for a 10year time frame from the year of the systematic reviews' last literature search.
Of the 157 metaanalyses surveyed, 47 included only trials published before 1996. Of the remaining 110 metaanalyses, 21 included trials that were all published in the last decade. Among the 89 metaanalyses that in cluded trials published in the last decade and earlier, exclusion of the data published before 1996 changed the level of statistical significance of the summary effects in 16; in 9 cases the summary effects became nonstatistic ally significant, and the opposite change was seen in 7 cases. The summary odds ratio for these 16 metaana lyses changed by a median of 23% (IQR 9%41%).
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Discussion of implications of including less recent studies. Only 12 of 157 systematic reviews (8%) dis cussed the possible implications of including older tri als. These included metaanalyses related to pregnancy and neonatal medicine (4), neuropsychiatric disease (4), pulmonary disease (2), diabetes mellitus (1) and chemotherapy for bladder cancer (1) . The authors of 2 of these reviews concluded that the year of publication was unlikely to matter; 10 reviews expressed some con cern, and 2 clearly stated the importance of revisiting the clinical question with new trials. Trials included in these 12 metaanalyses were significantly older than those included in the other 145 metaanalyses that did not discuss the age of the trials (p = 0.003).
Most of the systematic reviews that included trials published before 1986 (61/70) and 124 of the 136 sys tematic reviews that included trials published before 1996 did not discuss the age of the included trials. Four systematic reviews discussed the implications of including less recent data in their metaanalyses. One of these also performed a sensitivity analysis that in cluded only trials published in the last decade. The me dian year of publication for the trials included in these 4 systematic reviews showed no statistically significant difference than in the other 19, which did not discuss the age of the trials (p = 0.46). Overall, 7 of the 9 sys tematic reviews that included trials published before 1986 did not discuss the implications of including less recent trials.
Discussion
Our analysis suggests that, even with the best inten tions, evidencebased medicine has to rely on less re cent evidence. Even when results were corrected for the year of the last literature search, few systematic reviews containing metaanalyses in the CDSR included trials published in the preceding 5 years. Almost a third of these included no trials published in the last decade, and in another 10% the statistical signific ance of the result related to the study primary outcome would have been different had the data been limited to the last decade. Most of the systematic reviews did not ad dress the implications of including less recent data. Metaanalyses published in highprofile peerreviewed journals tend to address newer interventions than the average CDSR review. Ac cordingly, almost all of them in cluded some trials published in the last 5 years, and all of them in cluded some trials published in the last decade. Nevertheless, even in these metaanalyses, the large ma jority also included 1 or more older trials, and very few discussed the implications of including older evid ence. Typically, the lack of recent evidence did not result from the CDSR systematic reviews being out of date; in fact, the majority of systematic reviews that we analyzed had been updated in the last 2 years. Nonetheless, few systematic reviews discussed the implications of the time of publication on the relevance of the evidence.
Evidence should not be undervalued simply because of its age. The amount of data, regardless of year of pub lication, is limited for most health care topics, 1113 and we do not have the luxury of discarding trials simply be cause of their calendar year. In the case of topics for which welldesigned old clinical trials are still relevant and conclusive, it is imprudent, and even unethical, to conduct new trials.
Occasionally, earlier published results may differ from those reported in later publications.
1416
This may reflect bias, 1719 timedependent efficacy (e.g., when the treatment benefit decreases with longer followup), 20 quality differences, 21, 22 or chance. For example, in the case of vitamin E supplementation for prevention of morbidity and mortality in preterm infants, the review authors suggest caution in interpreting and applying current evidence. The available data span over a decade (19912002), a period in which many advances were made in the field of preterm care. 23 However, one can not generalize. Less recent trials are not necessarily of worse quality, 24, 25 smaller, 26 or less externally valid 4, 5 than newer ones. 2 Each topic needs a careful caseby case scrutiny of whether the available evidence is relev ant to current practice. The availability of evidence is sometimes further restricted by the lack of standardized outcomes across trials. Selective reporting of "positive" outcome results is an added threat.
2729
Some limitations should be discussed. Although we used a standardized approach to select the year of pub lication, a trial may be in progress for many years be fore any results are published. Most trials do not specify when they started and completed enrolment and fol lowup. Efficacy trials may take 3 to 10 or more years from the start of enrolment to publication. 17 Therefore, the proportion of recently conducted trials is likely even smaller than what we report on the basis of publication year.
Second, we used the CDSR for our primary analyses because it is widely considered the most allencom passing and uptodate source for current evidence on health care interventions. However, even the CDSR rep resents work in progress, and it does not capture all in terventions. 30 Furthermore, some review authors may choose to exclude, a priori, less recent studies, espe cially in fastmoving areas of research, by restricting search years or requiring the reporting of methodolo gical quality characteristics.
Our evaluation of systematic reviews published in medical journals was unavoidably more restricted, since some information (such as primary outcome) is not standardized and is readily available in the same detail as in the CDSR systematic reviews.
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We should also caution that decisionmaking based on nominal statistical significance is precarious. 31, 32 A change in statistical significance does not mean that the estimated effect size is altered beyond chance. Neither can it be attributed with certainty to less recent studies, since many underlying factors (including chance alone) contribute to the uncertainty of the effect estimate. Giv en that most metaanalyses had very limited data over all, there was large uncertainty in the estimated effect size in recent compared with less recent published data. Direct comparisons of recent against less recent data would be underpowered to show even major differences in effect sizes in these metaanalyses.
However, some empirical evidence suggests that, in some fields, smaller treatment effects may be en countered in more recent trials than in earlier re search. 1, 1416, 33 In the present evaluation, in the metaanalyses in which the formal statistical signific ance status of the summary effect changed with the ex clusion of less recent data, the median change in the odds ratio was also 23%. This is a considerable change, given that most medical interventions have modest ef fects.
Acknowledging these caveats, our survey suggests that even though the CDSR reviews are frequently up dated, evidence from very recently published studies for most health care interventions is scant. Although less re cent studies should not be discarded, clinicians should interpret medical evidence with attention to the applic ability and relevance of these studies to current clinical practice. If evidence on a specific topic is considered to be outdated or missing, and the review question re mains salient, the scientific community should be sensit ized toward conducting relevant targeted studies.
